Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedAug 02, 2026
DataAggregated Company Financials
Companies20
  • 7D-3.0%
  • 3M7.7%
  • 1Y-0.5%
  • YTD-7.7%

Over the last 7 days, the Healthcare industry has dropped 3.0%, driven by Novo Nordisk declining 4.4%. Meanwhile, Coloplast actually outperformed within the industry, gaining 6.4% in the last week. As for the longer term, the industry's performance has been flat for the past year. As for the next few years, earnings are expected to grow by 1.9% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 03 Aug 2026DKK 1.8tDKK 469.1bDKK 147.1b20.6x12.2x3.8x
Wed, 01 Jul 2026DKK 1.8tDKK 469.2bDKK 147.1b20.5x12.3x3.9x
Fri, 29 May 2026DKK 1.7tDKK 468.6bDKK 147.0b20.4x11.7x3.7x
Sun, 26 Apr 2026DKK 1.6tDKK 447.3bDKK 129.9b18.3x12x3.5x
Tue, 24 Mar 2026DKK 1.4tDKK 447.5bDKK 130.0b16.4x11.1x3.2x
Thu, 19 Feb 2026DKK 1.8tDKK 447.4bDKK 131.0b18.5x13.9x4.1x
Sat, 17 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Mon, 15 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b17.4x14.1x4.2x
Wed, 12 Nov 2025DKK 1.9tDKK 452.9bDKK 135.7b18.2x13.9x4.2x
Fri, 10 Oct 2025DKK 2.2tDKK 447.8bDKK 141.8b18.4x15.5x4.9x
Sun, 07 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.5x4.6x
Tue, 05 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.3x14.7x4.3x
Thu, 03 Jul 2025DKK 2.4tDKK 422.9bDKK 124.4b30.8x19.4x5.7x
Sat, 31 May 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Mon, 28 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.9x18.6x5.5x
Wed, 26 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.4x22.8x6.7x
Fri, 21 Feb 2025DKK 3.2tDKK 410.0bDKK 121.4b27.5x26.3x7.8x
Sun, 19 Jan 2025DKK 3.1tDKK 387.5bDKK 111.3b28.5x27.9x8x
Tue, 17 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.3x35.8x10.3x
Thu, 14 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b31.9x35.4x10.1x
Sat, 12 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Mon, 09 Sep 2024DKK 4.5tDKK 371.9bDKK 107.2b34.9x42.2x12.2x
Wed, 07 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b35.9x42.6x12.7x
Fri, 05 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.4x46x13.8x
Sun, 02 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.8x44.1x13.2x
Tue, 30 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b34.3x45.3x13.2x
Thu, 28 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.3x45.4x13.3x
Sat, 24 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Mon, 22 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.5x42.1x11.8x
Wed, 20 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.5x39.5x11.1x
Fri, 17 Nov 2023DKK 3.5tDKK 320.1bDKK 90.3b33.5x38.8x11x
Sun, 15 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b30.7x45x12.1x
Tue, 12 Sep 2023DKK 3.6tDKK 305.4bDKK 82.2b35.7x43.6x11.7x
Thu, 10 Aug 2023DKK 3.4tDKK 288.2bDKK 74.9b40.4x44.8x11.6x
Price to Earnings Ratio

44.8x


Total Market Cap: DKK 3.4tTotal Earnings: DKK 74.9bTotal Revenue: DKK 288.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 28.5x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.2x which is lower than its 3-year average PE of 28.5x.
  • The 3-year average PS ratio of 8.3x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-0.67%
Healthcare-2.95%
Life Sciences7.62%
Medical Equipment4.78%
Healthcare Services2.36%
Healthtech-0.03%
Biotech-0.085%
Pharma-4.25%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 32.8x.
    • Analysts are expecting annual earnings growth of 20.4%, which is higher than its past year's earnings growth of 5.2% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
COLO B ColoplastDKK 429.406.4%
+DKK 5.8b		-27.6%PE45.9x
DEMANT DemantDKK 281.002.7%
+DKK 1.6b		14.8%PE25x
AMBU B AmbuDKK 72.356.2%
+DKK 1.1b		-21.4%PE40x
ZEAL Zealand PharmaDKK 304.004.0%
+DKK 828.8m		-7.2%PE3.3x
GUBRA GubraDKK 386.809.4%
+DKK 542.3m		8.1%PE3.7x

Latest News

CHEMM
DKK 432.60
ChemoMetec
7D
6.2%
1Y
-11.0%
NOVO B
DKK 306.50
Novo Nordisk
7D
-4.4%
1Y
-0.7%
GUBRA
DKK 386.80
Gubra
7D
9.4%
1Y
8.1%
HLUN B
DKK 41.50
H. Lundbeck
7D
-1.5%
1Y
23.3%
GMAB
DKK 1,858.50
Genmab
7D
-1.1%
1Y
34.0%
EMBLA
DKK 28.30
Embla Medical hf
7D
0.5%
1Y
-12.4%
Analysis Article • Jul 24

Embla Medical hf. Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next

Embla Medical hf. ( CPH:EMBLA ) last week reported its latest second-quarter results, which makes it a good time for...
ZEAL
DKK 304.00
Zealand Pharma
7D
4.0%
1Y
-7.2%
Narrative Update • Jul 23

ZEAL: Future Returns Will Hinge On Obesity Pipeline Execution Timing

The updated analyst price target for Zealand Pharma moves to DKK 300 from DKK 400. This reflects a more cautious stance as analysts point to fewer near term catalysts, lower peak sales expectations for petrelintide and survodutide, and a higher assumed discount rate and future P/E in their models.
DEMANT
DKK 281.00
Demant
7D
2.7%
1Y
14.8%
Narrative Update • Jul 21

DEMANT: Growth Inflection Expectations In European Medtech Set To Drive Upside

The analyst price target for Demant has been raised from DKK 300 to DKK 310. Analysts point to modest adjustments in fair value, discount rate, revenue growth assumptions and future P/E expectations, alongside mixed recent rating changes that reflect both perceived growth potential and valuation constraints.
AMBU B
DKK 72.35
Ambu
7D
6.2%
1Y
-21.4%
Narrative Update • Jul 15

AMBU B: Margin Resilience And Competitive Response Are Expected To Drive Future Upside

The analyst price target for Ambu has been cut from DKK 138.0 to DKK 116.4, as analysts adopt more cautious assumptions around competition, growth, margins, discount rate and future P/E following recent bearish research updates. Analyst Commentary Recent research on Ambu has leaned more cautious, with some price targets and ratings adjusted to reflect concerns about competition and the near term outlook.
COLO B
DKK 429.40
Coloplast
7D
6.4%
1Y
-27.6%
Narrative Update • Jul 15

COLO B: Recent P/E Reset Will Create Upside Opportunity

Analysts have lowered the fair value estimate for Coloplast to DKK 584 from DKK 868, reflecting a reset in price assumptions and P/E expectations, while recent price targets across the Street range from DKK 345 to DKK 484. Analyst Commentary Recent Street research on Coloplast shows a wide spread in views, but there are several constructive signals that point to ongoing interest in the stock at current levels.
BAVA
DKK 177.90
Bavarian Nordic
7D
2.0%
1Y
-24.5%
ALK B
DKK 222.00
ALK-Abelló
7D
-2.2%
1Y
17.5%
Narrative Update • Jul 10

ALK B: Allergy Immunotherapy Leadership Will Drive Future Earnings Reassessment

Analysts have raised their price target on ALK-Abelló from DKK 185 to DKK 285, citing the company's position as a global leader in allergy immunotherapy and recent Street research that supports this view. What’s in the News for ALK-Abelló MHRA in the UK granted marketing authorisation for EURneffy 1 mg, the first needle-free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 kg to less than 30 kg.
MONSO
DKK 0.30
Monsenso
7D
-12.4%
1Y
12.9%